These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27629777)

  • 1. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
    Kwon J; Park M; Kim JH; Lee HW; Kang MC; Park JH
    Tumour Biol; 2015 Sep; 36(10):7449-56. PubMed ID: 25903467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
    Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
    Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality Treatment and Prognosis in Esophageal Squamous Cell Carcinoma Requiring Esophagectomy.
    Yamashita K; Katada N; Moriya H; Hosoda K; Sakuramoto S; Kikuchi S; Watanabe M
    Hepatogastroenterology; 2014 Jun; 61(132):1042-8. PubMed ID: 26158163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.
    Kuo IY; Chang JM; Jiang SS; Chen CH; Chang IS; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
    Int J Med Sci; 2014; 11(8):779-87. PubMed ID: 24936140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.
    Guo W; Dong Z; Cui J; Guo Y; Shen S; Guo X; Kuang G
    Clin Exp Metastasis; 2016 Jan; 33(1):73-85. PubMed ID: 26482475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus.
    Hibino S; Kanda M; Oya H; Takami H; Shimizu D; Nomoto S; Hishida M; Niwa Y; Koike M; Yamada S; Nishikawa Y; Asai M; Nakayama G; Fujii T; Sugimoto H; Fujiwara M; Kodera Y
    Oncol Rep; 2014 Feb; 31(2):693-700. PubMed ID: 24317529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
    Jin Z; Zhao Z; Cheng Y; Dong M; Zhang X; Wang L; Fan X; Feng X; Mori Y; Meltzer SJ
    Cancer; 2013 Oct; 119(20):3604-9. PubMed ID: 23893879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
    Otowa Y; Nakamura T; Yamamoto M; Kanaji S; Matsuda Y; Matsuda T; Oshikiri T; Sumi Y; Suzuki S; Kakeji Y
    Dis Esophagus; 2017 Dec; 30(12):1-5. PubMed ID: 28881893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
    Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
    World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.
    Konishi H; Fujiwara H; Shiozaki A; Hiramoto H; Kosuga T; Komatsu S; Ichikawa D; Okamoto K; Otsuji E
    Int J Clin Oncol; 2016 Feb; 21(1):95-101. PubMed ID: 26194809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.